Age-related Macular Degeneration (AMD)

Suraj Eye Institute · Medical Retina

Age-related Macular Degeneration (AMD)

EN: The leading cause of central vision loss after 60हिंदी: उम्र संबंधी मैक्युलर डीजेनेरेशनमराठी: वयोमानानुसार मॅक्युलर डीजनरेशन

Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration (AMD) is a slow, age-related deterioration of the macula — the part of the retina responsible for sharp central vision. It is the leading cause of central vision loss after the age of 60. AMD does not cause complete blindness — the side (peripheral) vision is preserved — but it makes reading, recognising faces, driving and detailed work difficult.

AMD is silent in its early stages. A yearly check after age 50 catches it long before symptoms appear — and modern treatment can dramatically slow it down.

The Two Types of AMD

AMD comes in two main forms, both starting from the same underlying ageing changes:

  • Dry AMD — the more common form (about 85% of cases). The macula slowly thins and accumulates deposits called drusen. Vision loss is gradual.
  • Wet AMD — less common (about 15% of cases) but causes most of the severe vision loss. Abnormal new blood vessels grow under the retina, leak fluid or blood, and rapidly damage the macula.

About 10–15% of patients with dry AMD will eventually develop wet AMD in one or both eyes. That is why anyone with dry AMD needs regular monitoring.

How AMD progresses — cross-section of the macula Normal Smooth macula Drusen Dry AMD — drusen Yellow deposits under retina Atrophy (loss) Geographic atrophy Cells in the macula die off Fluid & bleed Wet AMD — CNV New vessels leak & bleed Retina RPE Choroid
The progression of AMD across four panels. Drusen are the earliest sign; geographic atrophy is the advanced dry form; wet AMD develops when new vessels grow from the choroid into the retina.

Symptoms

Early AMD

  • Often no symptoms at all — the diagnosis is made on routine eye exam
  • Mild blurring or difficulty reading small print
  • Slightly slower adaptation when moving from bright light to dim light

Advanced dry AMD (geographic atrophy)

  • A central blurred or dark area that gradually expands
  • Faces become harder to recognise
  • Reading becomes slow and tiring

Wet AMD

  • Sudden distortion of straight lines
  • A new dark spot or smudge in the centre of vision
  • Sudden drop in central vision over days or weeks
  • Difficulty reading or doing fine work that was easy a week before
A sudden change in straight lines or a new dark central spot may be the start of wet AMD. This is an emergency — come the same day. Anti-VEGF treatment started within days protects vision far better than treatment started weeks later.

Who Is at Risk?

  • Age over 60 — the strongest risk factor
  • Family history of AMD
  • Smoking — doubles the risk; the most important modifiable factor
  • High blood pressure and cardiovascular disease
  • Long-term UV exposure without protection
  • Poor diet, obesity, low intake of green leafy vegetables and fish
  • Light iris colour (in some populations)

How We Diagnose AMD

  • Dilated retinal examination — the first step; drusen, pigment changes and bleeds are usually visible
  • OCT — the most important test. Shows drusen, fluid, atrophy and bleeds in cross-section
  • OCT-Angiography — detects abnormal new vessels (CNV) without any dye injection
  • Fundus autofluorescence (FAF) — maps areas of retinal cell loss
  • Fluorescein angiography and ICG angiography — for difficult cases, especially when ruling out polypoidal disease (PCV)
  • Amsler grid — for self-monitoring at home

Treatment

For Dry AMD

There is no medicine that fully cures dry AMD, but several steps slow the disease meaningfully:

  • AREDS2 vitamins — a specific combination of antioxidants, lutein, zeaxanthin and zinc reduces the risk of progression to advanced AMD by about 25% in eligible patients.
  • Diet rich in green leafy vegetables, fish, nuts and fruit.
  • Quit smoking completely.
  • Blood pressure and cardiovascular health.
  • UV protection — sunglasses and a hat outdoors.
  • Amsler grid weekly to catch conversion to wet AMD early.
  • Newer therapies for geographic atrophy (complement inhibitors) are emerging — we will advise if you are a candidate.

For Wet AMD

  • Intravitreal anti-VEGF injections — the cornerstone of wet AMD treatment. Drugs used include Ranibizumab, Aflibercept, Brolucizumab, Faricimab and Bevacizumab. The standard plan is three monthly loading injections, then maintenance based on OCT response.
  • Photodynamic Therapy (PDT) — mainly for polypoidal lesions; sometimes combined with anti-VEGF.
  • Submacular surgery — rarely needed, for very large submacular bleeds.
 Dry AMDWet AMD
FrequencyAbout 85% of casesAbout 15% of cases
How it developsSlow (years)Often rapid (days–weeks)
Main findingDrusen, then atrophyNew vessels, fluid, bleed
Risk of severe vision lossLower, gradualHigh if untreated
Main treatmentAREDS2, lifestyle, monitoringAnti-VEGF injections

What to Expect from Treatment

  • Wet AMD: Most patients stabilise; many gain some vision. Treatment is long-term — usually injections every 4–12 weeks, individualised.
  • Dry AMD: AREDS2 and lifestyle slow progression. Most patients keep useful vision for many years if monitored.
  • Both eyes need to be followed separately — AMD often develops in the second eye later.

Prevention & Self-Care

  • Do not smoke (or stop, if you do)
  • Eat green leafy vegetables, oily fish, fruits and nuts regularly
  • Maintain healthy blood pressure and weight
  • Wear UV-protective sunglasses outdoors
  • Amsler grid weekly if you have early AMD or a family history
  • Yearly dilated retinal exam after age 50; sooner if symptoms appear
  • Discuss AREDS2 supplements with us if you have intermediate or advanced AMD in one eye

When to Come to Us Immediately

A new dark spot, new distortion of straight lines, a sudden drop in central vision — come the same day. Wet AMD treated within days has a far better outcome than wet AMD treated after weeks.

In short: AMD is the most common cause of central vision loss in older adults — but with early diagnosis, AREDS2 for dry AMD, and modern injections for wet AMD, most patients keep useful vision for many years.

Frequently Asked Questions

Will I go completely blind from AMD?
No. AMD damages central vision but not peripheral vision. Most patients retain enough peripheral and intermediate vision to move around independently. Modern treatment further protects what you have.
Should I take AREDS2 supplements?
AREDS2 is helpful if you have intermediate or advanced AMD in one eye. It does not prevent AMD in healthy eyes. We will tell you whether it is appropriate for you and which brand to use.
I have dry AMD — will it become wet?
About 10–15% of patients with dry AMD develop wet AMD in one or both eyes over years. That is why we monitor regularly and ask you to use the Amsler grid at home.
How often will I need injections?
Wet AMD is usually treated with 3 monthly loading injections, then individualised maintenance. Some patients need injections every 4–6 weeks; others stretch to 12 weeks. The goal is the longest interval that keeps the eye dry on OCT.
Can AMD be cured?
Not yet. The goal of all treatment is to slow progression and protect remaining vision. New treatments are emerging every year — the field is moving rapidly.
Is AMD hereditary?
Family history is a risk factor, but lifestyle (especially smoking and diet) matters as much or more. Children of patients with AMD should start yearly retinal exams from age 50.
Are there low-vision aids that can help me read?
Yes. Magnifiers, high-contrast lighting, large-print books, audio books, screen readers and special spectacles all help. We will refer you for a low-vision assessment if needed.

Book an appointment for a retina evaluation at Suraj Eye Institute.

Book Appointment Now for Retina Evaluation

You cannot copy content of this page

Discover more from Suraj Eye Institute

Subscribe now to keep reading and get access to the full archive.

Continue reading